Krystal Biotech Inc. (KRYS) has been on a tear since securing FDA approval for its first product on May 19.
Vyjuvek, a topical gel approved for the treatment of dystrophic epidermolysis bullosa, is not only the first FDA-approved product for the company but is also the first-ever redosable gene therapy and the first and only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa, both recessive and dominant.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.